LLY News | Roxom Stocks

Invest Private Security

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Preferreds paying dividends in bitcoin.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Everything Roxom publishes, in one feed.

Product launches, listings, and company news.

Commentary and analysis from the Roxom team.

Research Reports

In-depth research on bitcoin capital markets.

Weekly market updates, delivered to your inbox.

Roxom in the news, and press resources.

Where to find us, online and in person.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LL

Mkt Cap

$1.043T

Volume

1.89M

Next Earnings

October 29th

Loading chart

LL

LLYEli Lilly & Co.

LLY

Pay with—

Available Balance0.00

LL

Mkt Cap

$1.038T

Volume

1.89M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHThe Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.The Motley Fool · Sep 23, 2026

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old ProblemsNovo Nordisk is rebranding to 'Novo' as it launches a pill version of its GLP-1 weight-loss drug to regain market share lost to Eli Lilly. While the company has a solid strategy with low pricing to drive volume, the name change alone won't address fundamental competitive challenges. The stock is down 70% from its 2024 high, though it trades at an attractive valuation with a 4.1% dividend yield.The Motley Fool · Sep 22, 2026

Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II StudyRoche reported positive Phase II results for enicepatide, its once-weekly dual GLP-1/GIP receptor agonist, showing dose-dependent HbA1c reductions of 2.65% and body weight loss of 15.5% at the 24 mg dose in type 2 diabetes patients. The drug was well-tolerated with minimal discontinuations. Roche is advancing two Phase III weight-management studies and plans to initiate Phase III glycemic-control and cardiovascular trials in H1 2027, positioning itself to compete in the growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.Zacks Investment Research · Sep 22, 2026

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.The Motley Fool · Sep 22, 2026

Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to KnowEli Lilly closed at $1,164.89, up 1.04% but underperforming the S&P 500's 1.49% gain. The stock declined 8.16% over the past month, trailing the broader market. Analysts expect strong earnings growth of 36.18% YoY with revenue projected at $22.08 billion (+25.46%), but the company trades at a premium valuation with a Forward P/E of 31.94 versus the industry average of 15.87. Eli Lilly holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 21, 2026

Why Twist Bioscience Stock Skyrocketed This WeekTwist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from the advanced research platform.The Motley Fool · Sep 18, 2026

4 Biotech Stocks to Watch as Potential Takeover TargetsBiotech M&A activity has accelerated sharply in 2026, with deal value reaching $130 billion in H1 alone. Four biotech companies—Abivax, Iovance Biotherapeutics, Viking Therapeutics, and BioCryst Pharmaceuticals—are highlighted as potential acquisition targets due to their differentiated late-stage assets and strategic positioning in high-growth therapeutic areas including immunology, oncology, obesity, and rare diseases.Zacks Investment Research · Sep 18, 2026

Better Buy for Cautious Investors: Eli Lilly vs CostcoThe article compares Eli Lilly and Costco as defensive stock picks for cautious investors amid market hesitation. Eli Lilly benefits from its dominant GLP-1 weight loss drug portfolio (Mounjaro and Zepbound), while Costco offers stability through its membership-based business model with high renewal rates. Despite both stocks being reasonably valued, the author recommends Costco as the better buy, trading at approximately 39x forward earnings compared to Eli Lilly's historical valuation levels.The Motley Fool · Sep 18, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding Stelara impact. However, J&J faces headwinds from Stelara's patent expiration, MedTech slowdown, and upcoming generic competition for other drugs. Despite these challenges, analysts recommend staying invested given the company's diversified portfolio, strong pipeline, and confident guidance.Zacks Investment Research · Sep 18, 2026

to start trading

LL

LLYEli Lilly & Co.

LLY

Pay with—

Available Balance0.00

Your PositionYou don't own any LLY yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$1.73

Yield0.59%

Annual$6.92